According to the research report titled ‘U.S. Direct-to-Consumer Genetic Testing Market Size By Test Type (Carrier Testing, Predictive Testing, Ancestry & Relationship Testing, Nutrigenomics Testing), By Technology (Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS)), Industry Analysis Report, Application Potential, Competitive Market Share & Forecast, 2019 - 2025’, available with Market Study Report, U.S. direct-to-consumer genetic testing market is projection to surpass a valuation of USD 850 million by the end of the forecast period 2019-2025.
 

Increasing cases of genetic disorders such as achondroplasia, Parkinson’s and Alzheimer’s diseases is accelerating U.S. direct-to-consumer genetic testing market growth. Rising public awareness regarding genetic tests, especially for preventive diagnostics, and subsequent spike in the demand for personalized genetic tests are the other major growth propellers of the industry.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2276199/
 

Further, emergence of technologically advanced solutions is positively impacting market demand. For instance, 23andMe Inc. manufactures DTC tests that leverages genotype testing technology for providing data on health, behavioral attributes, carrier status for studying drug interactions. Improving accessibility to such advanced tests for disease detection will spur the industry growth. However, high cost of these kits may hinder the industry remuneration in the upcoming years.
 

In terms of test type, U.S. direct-to-consumer genetic testing industry size from predictive testing segment is estimated to multiply at 16% CAGR over the forecast duration, attributable to rising burden of genetic diseases in the U.S. Predictive testing helps in disease detection prior to the onset of the diseases, in turn, reduces morbidity and mortality rate.
 

Considering technology, single nucleotide polymorphism (SNP) chips segment contributed about USD 140 million to the industry valuation in 2018 and will likely record strong gains in the upcoming years. SNP chip assist in evaluating gene sequences at a specific resolution that unravels details regarding faulty genes. Moreover, these chips further increase test efficiency by detecting changes at a molecular level, making them highly demanded in drug discovery field.
 

Speaking of the competitive landscape, direct-to-consumer genetic testing industry in the U.S. is currently defined by few companies, namely, Pathway Genomics (OmeCare), MyHeritage Ltd., Living DNA Ltd., Karmagenes SA, Identigene LLC, Helix OpCo LLC, Full Genomes Corp., Gene By Gene Ltd., EasyDNA, Color Genomics (Color Health Ltd.), Ancestry.com LLC, and 23andMe Inc.
 

Industry players are expanding investments in operational activities to offer reliable DTC tests to end-users. Apart from this, they are also undertaking strategies such as acquisitions, mergers, collaborations, new product launches, geographical expansions to improve their position in the marketplace. For instance, 23andMe Inc., in July 2018, announced collaboration with GlaxoSmithKline (GSK) to discover therapeutics for treating genetic diseases, helping it expand its market footprint.